Specimen Collection

2 mL CPD Blood (Preferred)

2 mL EDTA Blood
Turnaround Time: Between 2 weeks and 4 weeks
Diagnostic Use and Interpretation

CALR exon 9 mutations are found in approximately 65% of non-JAK2 mutated essential thrombocythemia and 85% of non-JAK2 mutated primary myelofibrosis. In both ET and PMF, CALR mutations are associated with a lower risk of thrombosis and longer overall survival than JAK2 mutations.

Klamfl et al. (2013) NEJM, 369(25):2379-2390

Contact Information

To contact the Molecular Haematology team please call:

Auckland City Hospital	(09) 307 4949
Lablink	ext 22000
Prof. Peter Browett (Haematologist)	ext 9090-86281
Dr. Imogen Caldwell (Haematologist)	ext 22006
Nikhil Ghallayan (Section Leader)	ext 22005
Molecular Haematology Office	ext 22005

For more information about the Molecular Haematology service at LabPLUS:

Molecular Haematology information page

Last updated at 15:36:59 07/03/2024